REMARKS

Following acceptance of this amendment, claims 1-25, 27, and 33-37 are pending. Applicants amend the claims to remove unintentional duplication, place them in form appropriate to US practice, and to reduce the filing fee by, *inter alia*, removing multiple dependency. Applicants amend the specification for purposes of adding the priority information. The attached Abstract has been placed on a separate sheet of paper according to US practice.

Respectfully submitted,

hmyst It

Amy H. Fix

Attorney for Applicant Registration No. 42,616

Date: 17 May 2006

GlaxoSmithKline

Corporate Intellectual Property

Five Moore Drive P.O. Box 13398

Research Triangle Park, NC 27709-3398

Phone: 919-483-8911 Facsimile: 919-483-7988

ABSTRACT

The present invention realtes generally to novel therapeutic compounds and more particularly to novel compounds, their use as GPR40 agonists, processes for their manufacture, and intermediate compounds useful in their preparation.